#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

Jun 29, 2026 Episode Page ↗
Overview

Peter Attia, MD, discusses GLP-1 receptor agonists (Ozempic, Wegovy, Zepbound) and their impact on muscle and bone health during weight loss. He examines lean mass loss, DEXA scan limitations, and strategies for preserving muscle and bone while using these medications.

At a Glance
9m 56s Duration
4 Topics
2 Concepts

Deep Dive Analysis

Introduction to GLP-1 Receptor Agonists and Muscle Impact

Evolution of GLP-1 Agonists and Weight Loss Appeal

Early Concerns: Lean Mass Loss with GLP-1s

Limitations of Clinical Trial Data and Patient Counseling

GLP-1 Receptor Agonists

These are drugs like Ozempic, Wegovy, and Zepbound, which initially served as niche diabetes medications but have evolved into significant weight-loss therapies. The third generation, like semaglutide, marked a 'step function change' in their efficacy for weight loss.

Lean Mass (on DEXA)

This refers to the non-fat components of body weight as measured by DEXA scans. Early observations with GLP-1 agonists showed a concerning 1:1 ratio of fat to lean mass loss, meaning half of the weight lost was lean mass, which can be misleading.

?
What are GLP-1 receptor agonists and why did they gain popularity for weight loss?

GLP-1 receptor agonists are drugs like Ozempic, Wegovy, and Zepbound, which evolved from niche diabetes drugs to breakthrough weight-loss therapies due to their significant impact on weight loss, particularly with third-generation compounds like semaglutide.

?
What were the initial concerns regarding lean mass loss with GLP-1 receptor agonists?

Early trials and clinical observations showed that people using GLP-1 agonists for weight loss seemed to lose a disproportionately high amount of lean mass, sometimes at a 1:1 ratio with fat, which was different from traditional weight loss methods.

?
How reliable are DEXA scans for measuring muscle loss during GLP-1 therapy?

DEXA scans can sometimes misrepresent true muscle loss, and early concerns about lean mass loss were based on these measurements, though the episode suggests a more nuanced understanding has emerged.

?
Do clinical trial results for GLP-1 agonists always reflect real-world outcomes?

Clinical trial data provides average, homogenized results and may not fully reflect outcomes when patients receive proper counseling on nutrition and exercise, suggesting that individual results can be improved with tailored guidance.

I mean, if I were to think about it through the arc of the story of these drugs, I think it was obviously the impact on weight loss.

Peter Attia

And it was almost a one-to-one ratio, which meant that if a person lost 10 pounds, five of them would be fat and five of them would be lean as it's characterized on DEXA.

Peter Attia

I think there's also been some fear mongering and speculating beyond what the data have shown.

Peter Attia
1:1 (fat to lean mass)
Weight loss ratio (early GLP-1 trials) If a person lost 10 pounds, five would be fat and five would be lean as characterized on DEXA in early observations.
2014
Year Peter Attia started experimenting with liraglutide His first clinical foray into GLP-1 agonists.
Fourth quarter of 2020
Quarter Peter Attia realized semaglutide was a step function change Internal realization about the efficacy of the third generation of GLP-1 agonists.